Stock Track | Immatics (IMTX) Soars 5% as Analysts Reaffirm Buy Ratings and Raise Price Targets

Stock Track11-19

Shares of Immatics N.V. (NASDAQ: IMTX) are soaring 5.07% in intraday trading on Tuesday, as the biotechnology company receives positive attention from Wall Street analysts. The stock's upward movement comes on the heels of reaffirmed Buy ratings and an increased price target from prominent research firms.

Mizuho Securities has maintained its Buy rating on Immatics, setting a price target of $23.00. This vote of confidence from Mizuho analyst Graig Suvannavejh, who covers the Healthcare sector, suggests a strong upside potential for the stock. Additionally, Guggenheim has not only reaffirmed its Buy rating but also raised its price target on Immatics to $19 from $16, further bolstering investor sentiment.

These positive analyst actions reflect growing optimism about Immatics' prospects in the biotechnology space. As investors digest these bullish signals from Wall Street, the stock's significant price increase today indicates that the market is responding favorably to the analysts' outlook. Traders and investors will likely continue to monitor Immatics closely for any further developments that could impact its growth trajectory.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1171630466?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-19 01:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1171630466","market":"hk","top_or_hot":-1,"title":"Stock Track | Immatics (IMTX) Soars 5% as Analysts Reaffirm Buy Ratings and Raise Price Targets","media":"Stock Track","content":"<p>Shares of Immatics N.V. (NASDAQ: IMTX) are soaring 5.07% in intraday trading on Tuesday, as the biotechnology company receives positive attention from Wall Street analysts. The stock's upward movement comes on the heels of reaffirmed Buy ratings and an increased price target from prominent research firms.</p>\n\n<p>Mizuho Securities has maintained its Buy rating on Immatics, setting a price target of $23.00. This vote of confidence from Mizuho analyst Graig Suvannavejh, who covers the Healthcare sector, suggests a strong upside potential for the stock. Additionally, Guggenheim has not only reaffirmed its Buy rating but also raised its price target on Immatics to $19 from $16, further bolstering investor sentiment.</p>\n\n<p>These positive analyst actions reflect growing optimism about Immatics' prospects in the biotechnology space. As investors digest these bullish signals from Wall Street, the stock's significant price increase today indicates that the market is responding favorably to the analysts' outlook. Traders and investors will likely continue to monitor Immatics closely for any further developments that could impact its growth trajectory.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Immatics (IMTX) Soars 5% as Analysts Reaffirm Buy Ratings and Raise Price Targets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Immatics (IMTX) Soars 5% as Analysts Reaffirm Buy Ratings and Raise Price Targets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-19 01:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Immatics N.V. (NASDAQ: IMTX) are soaring 5.07% in intraday trading on Tuesday, as the biotechnology company receives positive attention from Wall Street analysts. The stock's upward movement comes on the heels of reaffirmed Buy ratings and an increased price target from prominent research firms.</p>\n\n<p>Mizuho Securities has maintained its Buy rating on Immatics, setting a price target of $23.00. This vote of confidence from Mizuho analyst Graig Suvannavejh, who covers the Healthcare sector, suggests a strong upside potential for the stock. Additionally, Guggenheim has not only reaffirmed its Buy rating but also raised its price target on Immatics to $19 from $16, further bolstering investor sentiment.</p>\n\n<p>These positive analyst actions reflect growing optimism about Immatics' prospects in the biotechnology space. As investors digest these bullish signals from Wall Street, the stock's significant price increase today indicates that the market is responding favorably to the analysts' outlook. Traders and investors will likely continue to monitor Immatics closely for any further developments that could impact its growth trajectory.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMTX","symbol_name":"Immatics N.V.","start_time":0,"source_url":"","article_id":"1171630466","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1171630466","pubTimestamp":1763488698,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Immatics N.V. (NASDAQ: IMTX) are soaring 5.07% in intraday trading on Tuesday, as the biotechnology company receives positive attention from Wall Street analysts. The stock's upward...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IMTX":"Immatics N.V."},"translate_title":"个股追踪|分析师重申买入评级并上调目标价，Immatics(IMTX)飙升5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMTX":1},"content_text":"Shares of Immatics N.V. (NASDAQ: IMTX) are soaring 5.07% in intraday trading on Tuesday, as the biotechnology company receives positive attention from Wall Street analysts. The stock's upward movement comes on the heels of reaffirmed Buy ratings and an increased price target from prominent research firms.\nMizuho Securities has maintained its Buy rating on Immatics, setting a price target of $23.00. This vote of confidence from Mizuho analyst Graig Suvannavejh, who covers the Healthcare sector, suggests a strong upside potential for the stock. Additionally, Guggenheim has not only reaffirmed its Buy rating but also raised its price target on Immatics to $19 from $16, further bolstering investor sentiment.\nThese positive analyst actions reflect growing optimism about Immatics' prospects in the biotechnology space. As investors digest these bullish signals from Wall Street, the stock's significant price increase today indicates that the market is responding favorably to the analysts' outlook. Traders and investors will likely continue to monitor Immatics closely for any further developments that could impact its growth trajectory.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1171630466","isCrawlerRequest":true}